Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Joseph Douglas Lyon sold 10,830 shares of the business's stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $26.00, for a total value of $281,580.00. Following the sale, the insider now owns 7,314 shares in the company, valued at $190,164. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Joseph Douglas Lyon also recently made the following trade(s):
- On Thursday, April 4th, Joseph Douglas Lyon sold 5,443 shares of Corcept Therapeutics stock. The stock was sold at an average price of $26.00, for a total value of $141,518.00.
- On Monday, April 1st, Joseph Douglas Lyon sold 500 shares of Corcept Therapeutics stock. The stock was sold at an average price of $26.01, for a total value of $13,005.00.
- On Friday, February 16th, Joseph Douglas Lyon sold 1,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $26.00, for a total value of $26,000.00.
Corcept Therapeutics Stock Performance
Shares of CORT opened at $23.97 on Tuesday. Corcept Therapeutics Incorporated has a 52-week low of $20.84 and a 52-week high of $34.28. The business's 50 day moving average price is $23.99 and its two-hundred day moving average price is $25.15. The firm has a market cap of $2.50 billion, a PE ratio of 22.61 and a beta of 0.50.
Forget Bitcoin: This $8 Stock Is the Next Big Thing
From Behind the Markets | Ad
4x Better than Bitcoin
Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Get the name of the stock here >>>
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.21 by $0.04. Corcept Therapeutics had a return on equity of 24.19% and a net margin of 22.38%. The company had revenue of $146.80 million for the quarter, compared to analyst estimates of $141.19 million. During the same period in the prior year, the firm earned $0.14 earnings per share. Corcept Therapeutics's revenue for the quarter was up 38.9% on a year-over-year basis. Research analysts predict that Corcept Therapeutics Incorporated will post 0.97 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts recently commented on CORT shares. StockNews.com cut Corcept Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday. HC Wainwright upped their target price on Corcept Therapeutics from $38.00 to $40.00 and gave the company a "buy" rating in a report on Thursday, May 2nd. Finally, Truist Financial upped their target price on Corcept Therapeutics from $42.00 to $44.00 and gave the company a "buy" rating in a report on Thursday, May 2nd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $40.10.
Check Out Our Latest Stock Report on Corcept Therapeutics
Hedge Funds Weigh In On Corcept Therapeutics
A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Corcept Therapeutics by 2.6% during the fourth quarter. Vanguard Group Inc. now owns 9,537,532 shares of the biotechnology company's stock worth $309,779,000 after purchasing an additional 239,887 shares during the period. Parallel Advisors LLC raised its position in Corcept Therapeutics by 1.2% in the 4th quarter. Parallel Advisors LLC now owns 3,768,245 shares of the biotechnology company's stock valued at $122,393,000 after buying an additional 44,762 shares during the last quarter. Norden Group LLC purchased a new stake in Corcept Therapeutics in the 1st quarter valued at $50,081,000. Boston Trust Walden Corp raised its position in Corcept Therapeutics by 1.1% in the 4th quarter. Boston Trust Walden Corp now owns 1,846,924 shares of the biotechnology company's stock valued at $59,988,000 after buying an additional 19,877 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Corcept Therapeutics by 4.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 900,444 shares of the biotechnology company's stock valued at $29,246,000 after buying an additional 39,111 shares during the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.
Corcept Therapeutics Company Profile
(
Get Free Report)
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
